Nucleotide-modified covalent G4 DNA enzyme, preparation method thereof and application of nucleotide-modified covalent G4 DNA enzyme in in-vitro diagnosis
By covalent binding of nucleotide modification on the G4 structure, an efficient covalent G4 DNA enzyme was formed, which solved the problems of low catalytic efficiency and strong metal ion dependence of existing G4/Hemin DNA enzymes, and achieved in vitro diagnosis Efficient applications in the HER2 protein, especially in situ imaging detection.
Patent Information
- Application Number
- CN202411234953.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-09-04
- Publication Date
- 2024-11-29
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
The existing G4/Hemin DNA enzyme has low catalytic efficiency, high background signal and strong dependence on metal ions, which limits its application in in vitro diagnosis.
Covalently bind heme chloride, ligand nucleotides and G4 structures through amide reaction, modifying nucleotides at the 3' or 5' end of the G4 structure to form a nucleotide-modified covalent G4 DNA enzyme, reducing metals Ion dependence and improve catalytic activity.
It has achieved high catalytic activity, strong environmental tolerance and weak metal ion dependence, significantly improved the catalytic performance of enzymes, and is suitable for in vitro diagnosis, especially in the HER2 protein in situ imaging detection of breast cancer cells and tissues, and is highly efficient and Specificity.
Smart Images

Figure CN119040299A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biotechnology, and in particular to a nucleotide-modified covalent G4 DNA enzyme and a preparation method thereof and an application thereof in in vitro diagnosis. Background Art
[0002] G4 / Hemin DNA enzyme is a DNA enzyme with horseradish peroxidase (HRP)-like catalytic activity formed by G-quadruplex (G4) and hemin (Hemin) molecules through π-π stacking. Compared with the natural protease HRP, G4 / Hemin DNA enzyme has the advantages of small size, easy synthesis, high thermal stability, and rational design of allosteric control. Through the precise design of nucleic acid sequences and chemical modification of small molecules, it can be combined with nucleic acid molecular detection technologies such as DNA dynamic self-assembly and isothermal amplification to achieve the switch regulation of enzyme catalytic activity. It is a powerful catalytic tool and signal output element in the fields of biosensors, biomaterials and biomolecular devices. However, G4 / Hemin DNA enzyme still faces challenges such as weak catalytic efficiency, high background signal and strong dependence on metal ions. Its catalytic activity can be improved by adding exogenous activity enhancers or modifying the G4 sequence and Hemin molecular structure, but the enzyme activity enhancement effect is still relatively mild and has a strong dependence on metal ions.
[0003] For example, the invention patent CN107119031A discloses a novel thermophilic four-membered G-quadruplex DNA enzyme that enhances catalytic activity at the adjacent position of adenine and has high catalytic activity at high temperature. The enzyme is formed by annealing a DNA sequence rich in G bases with modified adenine bases at both ends at 95°C for 5 minutes in a buffer containing 150mM ammonium ions, and then cooling to form a four-membered G-quadruplex structure, which is combined with heme to form. The enzyme is simple to prepare and has good thermal stability, but it still has a strong dependence on metal ions, which limits its application. The invention patent CN111705044A discloses a strategy for enhancing the catalytic activity of meta-cytosine and achieving high catalytic activity G-quadruplex DNA enzyme by modifying cytosine. The enzyme is formed by heating a DNA sequence rich in G bases with modified cytosine bases at one end at 95°C for 5 minutes in a buffer containing 100mM potassium ions, annealing and cooling to form an intramolecular G-quadruplex structure, and combining with heme to form a DNA enzyme. The enzyme has the advantages of simple synthesis process, low price, easy storage, and clear activation site. It can achieve the same order of magnitude of enzyme activity as natural enzymes. However, the cytosine derivative raw materials used in this invention to enhance the catalytic activity need to be modified and are not easy to obtain, and the catalytic ability of the enzyme still needs to be further improved.
[0004] With the vigorous development of the in vitro diagnostic industry, the demand for G4 / Hemin DNA enzymes in the future market and research fields will further increase. Developing new G4 / Hemin DNA enzymes from the perspective of molecular structure, further improving their catalytic activity and environmental tolerance, and reducing their dependence on metal ions will be able to show stronger advantages in complex catalytic environments, and will have more important clinical value and better transformation prospects. Summary of the invention
[0005] In view of the shortcomings of the prior art mentioned above, the purpose of the present invention is to provide a nucleotide-modified covalent G4 DNA enzyme and a preparation method and application in in vitro diagnosis. The enzyme is a new type of G4 / Hemin DNA enzyme with a compact structure and an HRP-like catalytic active center. It has high catalytic activity, strong environmental tolerance and weak metal ion dependence, and is simple to synthesize and easy to store, and has great potential for in vitro diagnostic applications.
[0006] To achieve the above-mentioned purpose and other related purposes, the first aspect of the present invention provides a nucleotide-modified covalent G4 DNA enzyme, comprising Hemin, a ligand nucleotide and a G4 structure covalently bound in sequence through an amide reaction, wherein the ligand nucleotide is modified at the 3' end and / or the 5' end of the G4 structure, the ligand nucleotide comprises 1 to 3 bases, and the base of the ligand nucleotide is selected from at least one of adenine (A), thymine (T), and cytosine (C).
[0007] In some embodiments, the nucleotide sequence of the G4 structure is GGGTGGGTGGGTGGG.
[0008] In some embodiments, the base of the ligand nucleotide is selected from adenine (A) and / or thymine (T).
[0009] In some embodiments, the ligand nucleotide is modified at the 3' end of the G4 structure.
[0010] In some embodiments, the nucleotide sequence of the nucleotide-modified covalent G4 DNA enzyme is selected from at least one of SEQ ID NOs. 1 to 19:
[0011] SEQ ID NO.1: GGGTGGGTGGGTGGGAAA;
[0012] SEQ ID NO.2:GGGTGGGTGGGTGGGTTT;
[0013] SEQ ID NO.3: GGGTGGGTGGGTGGGCCC;
[0014] SEQ ID NO.4:TTGGGTGGGTGGGTGGGTC;
[0015] SEQ ID NO.5:GGGTGGGTGGGTGGGAA.
[0016] SEQ ID NO.6:GGGTGGGTGGGTGGGTT.
[0017] SEQ ID NO.7:GGGTGGGTGGGTGGGCC;
[0018] SEQ ID NO.8:GGGTGGGTGGGTGGGA.
[0019] SEQ ID NO.9:GGGTGGGTGGGTGGGT.
[0020] SEQ ID NO.10:GGGTGGGTGGGTGGGC;
[0021] SEQ ID NO.11:AGGGTGGGTGGGTGGGG.
[0022] SEQ ID NO.12:TGGGTGGGTGGGTGGG.
[0023] SEQ ID NO.13:CGGGTGGGTGGGTGGGG.
[0024] SEQ ID NO.14:AAGGGTGGGTGGGTGGGG.
[0025] SEQ ID NO.15:TTGGGTGGGTGGGTGGGG.
[0026] SEQ ID NO.16:CCGGGTGGGTGGGTGGGG.
[0027] SEQ ID NO.17:AAAGGGTGGGTGGGTGGGG.
[0028] SEQ ID NO.18:TTTGGGTGGGTGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGGG out.
[0029] SEQ ID NO.19:CCCGGGTGGGTGGGTGGG.
[0030] In this case, the present invention consists of a G4 DNA fragment consisting of SEQ ID NO.1, SEQ IDNO.3, and SEQ ID NO.4One license plate.
[0031] The second aspect of the present invention provides a method for preparing the nucleotide-modified covalent G4 DNA enzyme according to the first aspect, comprising: covalently bonding hemin, a ligand nucleotide and a G4 structure in sequence through an amide reaction to obtain the nucleotide-modified covalent G4 DNA enzyme.
[0032] In some embodiments, the method for preparing the nucleotide-modified covalent G4 DNA enzyme comprises: covalently combining the G4 structure modified with the ligand nucleotide at the 3' end and / or the 5' end with hemin through an amide reaction to obtain the nucleotide-modified covalent G4 DNA enzyme.
[0033] In some embodiments, the amide reaction process includes: mixing and incubating the G4 structure modified with the amino group (NH2) and the 3' end and / or the 5' end with the ligand nucleotide (nucleotide-modified G4 DNA-NH2) with hemin-coupled N-hydroxysuccinimide (Hemin-NHS) to obtain the nucleotide-modified covalent G4 DNA enzyme. Further, in some embodiments, the incubation temperature is 0 to 8°C, and the incubation time is not less than 12 hours, preferably 20 to 36 hours.
[0034] The third aspect of the present invention provides an in vitro diagnostic composition, comprising the nucleotide-modified covalent G4 DNA enzyme as described in the first aspect and / or the nucleotide-modified covalent G4 DNA enzyme prepared according to the method described in the second aspect.
[0035] In some embodiments, the in vitro diagnostic composition further comprises a peroxidase substrate, hydrogen peroxide (H2O2).
[0036] In some embodiments, the peroxidase substrate is selected from 2,2'-Azino-bis(3-ethylbenzothiazoline-6-sulfonic acid), ABTS or 10-Acetyl-3,7-dihydroxyphenoxazine (ADHP).
[0037] The nucleotide-modified covalent G4 DNA enzyme provided by the present invention has a catalytic ability equivalent to that of HRP. Therefore, it can be combined with a peroxidase substrate and hydrogen peroxide (H2O2) to construct a catalytic system such as an ABTS-H2O2 colorimetric system, an ADHP-H2O2 fluorescence system, or combined with microfluidic droplet technology to construct a microfluidic droplet catalytic system to develop an efficient in vitro diagnostic detection tool.
[0038] In some embodiments, the in vitro diagnostic composition also includes a first probe, a second probe and fluorescein tyramide, wherein the first probe is composed of a human epidermal growth factor receptor-2 (HER2) aptamer (Aptamer, Apt) and a primer exchange reaction (Primer Exchange Reaction, PER) amplification primer sequence, and is used to identify HER2 protein; the second probe is composed of the nucleotide-modified covalent G4 DNA enzyme sequence and a PER amplification chain complementary sequence, and the PER amplification chain complementary sequence is a long single-stranded complementary sequence generated by multi-stage PER amplification of the PER amplification primer sequence, for example, a long single-stranded complementary sequence generated by tertiary PER amplification of the PER primer sequence.
[0039] In some embodiments, the in vitro diagnostic composition further comprises a DNA polymerase for in situ amplification of PER, wherein the DNA polymerase includes but is not limited to Bst polymerase and the like.
[0040] According to the composition provided in the above embodiment, a HER2 protein in situ imaging detection system can also be constructed by using the nucleotide-modified covalent G4 DNA enzyme provided by the present invention, the first probe, the second probe and fluorescein tyramide, and the HER2 protein on the cell surface and the HER2 protein on the surface of formalin-fixed and paraffin-embedded (FFPE) tissue samples can be specifically detected by combining the efficient catalysis of the nucleotide-modified covalent G4 DNA enzyme and the HER2 protein in situ detection strategy of PER amplification.
[0041] In some embodiments, the in vitro diagnostic composition further comprises a buffer, which includes but is not limited to Tris-HCl buffer, PBS buffer, HEPES buffer, and the like.
[0042] The fourth aspect of the present invention provides the use of the nucleotide-modified covalent G4 DNA enzyme according to the first aspect and / or the nucleotide-modified covalent G4 DNA enzyme prepared according to the method described in the second aspect and / or the in vitro diagnostic composition according to the third aspect in the preparation of in vitro diagnostic reagents and / or the development of in vitro diagnostic systems.
[0043] As described above, the nucleotide-modified covalent G4 DNA enzyme of the present invention and its preparation method and application in in vitro diagnosis have the following beneficial effects:
[0044] 1. The nucleotide-modified covalent G4 DNA enzyme provided by the present invention exhibits catalytic ability comparable to that of HRP in both homogeneous and localized droplets, and its catalytic performance is superior to that of traditional G4 / Hemin DNA enzyme; moreover, the catalytic ability of the nucleotide-modified DNA enzyme constructed by a covalent manner is significantly higher than that of the non-covalent G4 DNA enzyme disclosed in other prior arts (e.g., invention patents CN107119031A and CN111705044A).
[0045] 2. Compared with traditional G4 / Hemin DNA enzyme, the nucleotide-modified covalent G4 DNA enzyme provided by the present invention has weaker metal ion dependence and environmental tolerance, and shows stronger advantages in complex catalytic environments.
[0046] 3. The nucleotide-modified covalent G4 DNA enzyme provided by the present invention can be combined with PER isothermal amplification technology for in situ imaging of HER2 protein on breast cancer cells and tissues, confirming its application value as a signal reporting element in the field of in vitro diagnosis. BRIEF DESCRIPTION OF THE DRAWINGS
[0047] Figure 1 Shown are (A) schematic diagrams of the structures of four DNA enzymes (traditional G4 / Hemin DNA enzyme C-G4 / H, zipper-type G4 / Hemin DNA enzyme Z-G4A / H, covalent G4 DNA enzyme Co-G4 / H without nucleotide modification, and covalent G4 DNA enzyme Co-G4A / H with nucleotide modification) and HRP in Example 1 of the present invention; as well as (B) the colorimetric spectrum of the product at 400-500nm in the ABTS-H2O2 colorimetric system and (C) the colorimetric kinetic analysis of the product at 418nm, and (D) the fluorescence emission spectrum of the product at 585nm in the ADHP-H2O2 fluorescence system.
[0048] Figure 2 The effect of the type and position of nucleotide modification on the catalytic activity of the covalent G4 DNA enzyme in Example 1 of the present invention is shown: (A) colorimetric kinetic analysis of the product at 418 nm in the ABTS-H2O2 system; (B) fluorescence kinetic analysis of the product at 585 nm in the ADHP-H2O2 fluorescence system.
[0049] Figure 3 Shown are (A) schematic diagram of the G4 topological structure in Example 1 of the present invention; (B) circular dichroism spectra of the antiparallel G4 sequence PS2.M, (C) hybrid G4 sequence TA, and (D) parallel G4 sequence G3T in 50 mM Tris-HCl (pH 7.0, without KCl) buffer.
[0050] Figure 4It shows the different DNA enzymes (C-G4 / H, Z-G4A / H, Co-G4 / H, Co-G4A / H, covalent G4 DNA enzyme Co-G4A / H3 with modified adenine nucleotide at 3' end, covalent G4 DNA enzyme Co-G4C / H3 with modified cytosine nucleotide at 3' end, covalent G4 DNA enzyme Co-G4 / H3 with unmodified adenine nucleotide at 3' end, covalent G4 DNA enzyme Co-G4A / H5 with modified adenine nucleotide at 5' end, and covalent G4 DNA enzyme Co-G4 / H5 with unmodified adenine nucleotide at 5' end) in Example 1 of the present invention at different pH, H2O2 concentration, K + Colorimetric rate results for concentration (AC).
[0051] Figure 5 Shown are the experimental results of comparing the catalytic performance of three DNA enzymes (Co-G4A / H3, Co-G4 / H3, C-G4 / H) and HRP in droplets in Example 1 of the present invention.
[0052] Figure 6 The results show the detection of HER2 protein on the surface of MDA-MB-231, MCF-7 and SKBR3 cells by the highly efficient catalysis and PER amplification of the nucleotide-modified covalent G4 DNA enzyme Co-G4A / H3 in Example 1 of the present invention: (A) fluorescence microscope; (B) flow cytometry.
[0053] Figure 7 Shown are the detection results of the HER2 protein in breast cancer tissues with different HER2 expression levels by the nucleotide-modified covalent G4 DNA enzyme Co-G4A / H3 efficient catalysis and PER amplification in Example 1 of the present invention.
[0054] Figure 8 Shown are the ultraviolet-visible (UV-vis) absorption spectra (A) and colorimetric kinetic experimental results (B) of the products obtained from the ABTS-H2O2 colorimetric system reaction constructed based on four DNA enzymes (A5A / H, G4TC / H, Co-G4TC / H, Co-G4A / H) in Example 2 of the present invention. DETAILED DESCRIPTION
[0055] The following describes the embodiments of the present invention through specific examples, and those skilled in the art can easily understand other advantages and effects of the present invention from the contents disclosed in this specification. The present invention can also be implemented or applied through other different specific embodiments, and the details in this specification can also be modified or changed in various ways based on different viewpoints and applications without departing from the spirit of the present invention.
[0056] In the present invention, unless otherwise specified, the term "plurality" means two or more.
[0057] The character " / " indicates that the objects before and after are in an "or" relationship. For example, A / B means: A or B.
[0058] The term "and / or" is a description of the association relationship between objects, indicating that three relationships can exist. For example, A and / or B means: A or B, or, A and B.
[0059] The nucleotide sequences involved in the present invention can be synthesized by biological companies with reference to existing technologies.
[0060] The following specific examples are given to illustrate the present invention in detail. It should also be understood that the following examples are only used to specifically illustrate the present invention and cannot be understood as limiting the scope of protection of the present invention. Some non-essential improvements and adjustments made by those skilled in the art based on the above content of the present invention belong to the scope of protection of the present invention. The specific process parameters and the like in the following examples are also only examples within a suitable range, that is, those skilled in the art can make a selection within a suitable range according to the description herein, and are not limited to the specific values exemplified below.
[0061] The G4 / Hemin DNA enzyme sequences involved in the following examples are shown in Table 1 below:
[0062] Table 1
[0063] G4 / Hemin DNase Sequence (5'-3') C-G4 / H GGGTGGGTGGGTGGG / Hemin Z-G4A / H GGGTGGGTGGGTGGGAAA / Hemin Co-G4 / H GGGTGGGTGGGTGGG-Hemin Co-G4A / H, Co-G4A / H3 GGGTGGGTGGGTGGGAAA-Hemin Co-G4A / H5 AAAGGGTGGGTGGGTGGG-Hemin Co-G4T / H, Co-G4T / H3 GGGTGGGTGGGTGGGTTT-Hemin Co-G4T / H5 TTTGGGTGGGTGGGTGGG-Hemin Co-G4C / H, Co-G4C / H3 GGGTGGGTGGGTGGGCCC-Hemin Co-G4C / H5 CCCGGGTGGGTGGGTGGG-Hemin
[0064] Note: C-G4 / H, Z-G4A / H are derived from Zippered G-quadruplex / hemin DNAzyme: exceptional catalyst for universal bioanalytical applications, Jia Li, NucleicAcids Research.
[0065] Example 1
[0066] This example studies the catalytic ability of nucleotide-modified covalent G4 DNA enzymes and optimizes their sequences. It also explores their application prospects in microfluidic droplet catalysis and in situ imaging of surface protein markers of tumor cells and tissue samples. The specific implementation process is as follows:
[0067] 1. Experimental Methods
[0068] 1. Determination of Enzyme Activity of Nucleotide-modified Covalent G4 DNA Enzyme
[0069] Nucleotide-modified G4 DNA-NH2 (25 μM) was mixed with hemin-NHS (25 μM) in HEPES buffer (200 mM HEPES, 10 mg / mL EDC, 0.1 mg / mL DMAP, 50% DMSO, pH 4.5), and then incubated at 4°C for 24 hours to obtain nucleotide-modified covalent G4 DNA enzyme.
[0070] The annealed nucleotide-modified covalent G4 DNA enzyme was diluted to a concentration of 45 nM using 50 mM Tris-HCl buffer. ABTS (2 mM) and H2O2 (50 mM) were then added for reaction. The colorimetric spectroscopy experiment collected the UV-vis absorption spectrum of the product in the range of 400 to 500 nm and analyzed the product. The colorimetric kinetic experiment was performed at 418 nm with a reaction time of 120 seconds. Similarly, covalent G4 DNA enzyme (9 nM), ADHP (100 nM) and H2O2 (1 mM) were added to the fluorescence experiment. The excitation wavelength of the fluorescent product was 558 nm, the emission wavelength was 585 nm, and the fluorescence spectrum was collected in the range of 550 to 650 nM to analyze the product. The fluorescence kinetic experiment was performed at 585 nm with a reaction time of 180 seconds.
[0071] 2. Construction of microfluidic droplet catalytic system based on nucleotide-modified covalent G4 DNA enzyme
[0072] A cross-shaped fluid focusing chip was designed to generate monodisperse microdroplets: fluorinated oil HFE-7500 containing 3% (w / w) F-SiO2-NPs was used as the continuous phase, the aqueous phase was used as the dispersed phase, Tris-HCl buffer containing nucleotide-modified covalent G4 DNA enzyme was injected into one side of the dispersed phase, and Tris-HCl buffer containing substrates ADHP and H2O2 was injected into the other side. The flow rates of the continuous phase and the dispersed phase were 0.3 and 0.1 mL / h, respectively. After droplets of uniform size were generated, the enzyme-catalyzed droplets were incubated at room temperature, and after the fluorescence signal reached stability, the fluorescent droplets were observed in the grooves of the chip using an inverted fluorescence microscope to collect the fluorescence signal.
[0073] 3. The HER2 protein in situ imaging detection system based on nucleotide-modified covalent G4 DNA enzyme and its basic principle are as follows:
[0074] 3.1 Basic principles:
[0075] First, the HER2 protein is recognized using the first probe composed of the HER2 aptamer and the primer exchange reaction (PER) amplification primer sequence (i.e., the HER2-Apt-PER amplification complex), and Bst polymerase is added for the first PER in situ amplification to produce a long single-stranded repeating specific sequence, followed by two branched PER amplifications. Finally, the pre-annealed second probe (the second probe is a complex composed of a nucleotide-modified covalent G4 DNA enzyme sequence and a complementary sequence of the tertiary PER amplification chain) is added for incubation to achieve the attachment of the DNA enzyme to the cell surface, and the highly sensitive in situ imaging of the HER2 protein is achieved by catalyzing the deposition of fluorescein tyramide on the cell surface.
[0076] 3.2 In situ imaging detection system for HER2 protein on cell surface
[0077] Human breast cancer cell lines SKBR3, MDA-MB-231 and MCF-7 were seeded on TC (Tissue culture treated) slides in 24-well cell culture plates. The culture medium was DMEM supplemented with 10% fetal bovine serum, 1% penicillin and streptomycin, and the cell culture plates were then cultured in an incubator at 37°C with 5% CO2. When the cells reached 60% confluency, the culture medium was removed and the cells were fixed with 4% paraformaldehyde for 15 minutes at room temperature. The cells were then washed three times with 1× PBS buffer, treated with 3% H2O2 for 30 minutes to inhibit endogenous peroxidase activity, and treated with 1× PBS buffer containing 3% BSA and 0.4mg / ml salmon sperm DNA to block nonspecific binding sites, and incubated at 37°C for 1 hour. Washed twice again with 1× PBS. 200 μL of 200 nM HER2-Apt-PER amplification complex was added to the 24-well plate and incubated at 37°C for 1 hour. Then, 200 μL of 1 μM fluorescent probe FAM and pre-annealed second probe were added to the cells to allow for sufficient hybridization and reacted at 37°C for 1 hour. TM The reaction solution of 488 tyramide reagent (1:200) and 0.03% H2O2 was added to the slide, the system was catalyzed at room temperature, and incubated in the dark for 10 minutes. The cell nuclei were stained with DAPI solution. After each step, the cells were washed three times with 1× PBS containing 0.05% Tween 20 for 5 minutes each time. Finally, the cells were observed using a DMi8 inverted fluorescence microscope (Leica, Germany).
[0078] For flow cytometry experiments, 10 6 The single cell suspension of each cell was incubated with the corresponding probe, and then reacted with tyramide reagent and H2O2. The fluorescence intensity of the cells was analyzed using FC-500 flow cytometer (Beckman Coulter).
[0079] 3.3. In situ imaging detection system for HER2 protein on the surface of formalin-fixed and paraffin-embedded (FFPE) tissues
[0080] FFPE tissue samples of breast cancer patients were placed in a 60℃ oven for 2 hours, then immersed in xylene for 8 minutes, and then dewaxed on a fully automatic intelligent staining machine DP260 (Dakewe, China): anhydrous ethanol, 95% ethanol, 85% ethanol and 75% ethanol, 3 minutes each step. Then heated at 100℃ in 1×PBS buffer for 20 minutes, slowly cooled to room temperature, and washed 3 times with 1×PBS buffer to complete antigen repair. For the detection of breast cancer FFPE samples: First, oligonucleotides (DNA) were coupled with recombinant anti-HER2 antibodies to form DNA-recombinant anti-HER2 antibody complexes. The specific coupling steps were performed according to the commercial kit of Abcam (ab218260). Subsequently, endogenous peroxidase activity was inhibited and nonspecific binding sites were blocked at the same time. The specific steps were the same as the previous cell detection. Then 10μl 1mg / ml DNA-recombinant anti-HER2 antibody complex was incubated with breast cancer FFPE samples at 37℃ for 1 hour. After incubation, the second probe was added and hybridized again at 37℃ for 1 hour. The subsequent fluorescence imaging steps were the same as the cell surface tyramide deposition experiment.
[0081] 2. Experimental Results Analysis
[0082] 1. Catalytic ability of nucleotide-modified covalent G4 DNA enzymes
[0083] See also Figure 1 The experimental results showed that for the ABTS-H2O2 colorimetric system: the nucleotide-modified covalent G4 DNA enzyme Co-G4A / H showed significantly improved catalytic activity compared with the traditional G4 / Hemin DNA enzyme C-G4 / H, Z-G4A / H, and the non-nucleotide-modified covalent G4 DNA enzyme Co-G4 / H, and the signal peak of Co-G4A / H at 418nm was about 4 / 5 of that of HRP, significantly narrowing the gap with HRP; for the ADHP-H2O2 fluorescence system: the nucleotide-modified covalent G4 DNA enzyme Co-G4A / H also showed catalytic ability comparable to that of HRP.
[0084] See also Figure 2The experimental results show that: whether modified at the 3' end or the 5' end, adenine and cytosine nucleotide modifications show excellent auxiliary enhancement effects on the catalytic performance of covalent G4 DNA enzymes (Co-G4A / H5, Co-G4C / H5, Co-G4A / H3, Co-G4C / H3), while thymine modification has no auxiliary enhancement effect on the catalytic performance of covalent G4 DNA enzymes (Co-G4T / H5, Co-G4T / H3); in particular, the covalent G4 DNA enzyme (Co-G4A / H3) with adenine nucleotide modified at the 3' end showed the strongest catalytic activity in both the ABTS-H2O2 colorimetric and ADHP-H2O2 fluorescence systems.
[0085] Figure 1 and Figure 2 The combination can indicate that the nucleotide-modified covalent G4 DNA enzyme has better catalytic ability than the traditional G4 / Hemin DNA enzyme, and can efficiently catalyze colorimetric and fluorescent reactions.
[0086] 2. Metal ion dependence and environmental tolerance of nucleotide-modified covalent G4 DNA enzymes
[0087] See also Figure 3 The experimental results show that covalent modification behavior can not only promote the formation of G4 structure, but also reduce its dependence on metal ions.
[0088] See also Figure 4 The experimental results show that adenine nucleotide accelerates the intermediate product Ⅰ (intermediate product Ⅰ refers to the catalysis of ABTS by G4DNA enzyme 2- The formation of intermediates in the reaction process of nucleotides and H2O2) to simulate the role of His42 in HRP is one of the important reasons for the improvement of the catalytic ability of nucleotide-modified covalent G4 DNA enzymes, and the nucleotide-modified covalent G4 DNA enzymes (Co-G4A / H, Co-G4A / H3, Co-G4C / H3, Co-G4A / H5) showed the weakest K + Dependence and the strongest environmental tolerance.
[0089] Figure 3 and Figure 4 The combination can illustrate that the nucleotide-modified covalent G4 DNA enzyme has weaker metal ion dependence and the strongest environmental tolerance.
[0090] 3. Catalytic performance of nucleotide-modified covalent G4 DNA enzymes in droplets
[0091] See also Figure 5The experimental results show that the catalytic performance of the nucleotide-modified covalent G4 DNA enzyme Co-G4A / H3 in droplets is higher than that of the non-nucleotide-modified covalent G4 DNA enzyme Co-G4 / H3 and the traditional G4 / Hemin DNA enzyme C-G4 / H, and has a catalytic ability comparable to that of HRP. The above results show that the nucleotide-modified covalent G4 DNA enzyme also has a catalytic ability comparable to that of HRP in droplets.
[0092] 4. Feasibility and specificity of the in situ detection strategy of HER2 protein with efficient catalysis and PER amplification by nucleotide-modified covalent G4 DNA enzyme
[0093] See also Figure 6 The experimental results showed that no obvious fluorescence signals were observed in MDA-MB-231 cells and MCF-7 cells with low HER2 protein expression, while strong green fluorescence signals were produced on the surface of SKBR3 cells with high HER2 protein expression. The above results show that the HER2 protein in situ detection strategy of nucleotide-modified covalent G4 DNA enzyme efficient catalysis and PER amplification is feasible and specific for detecting cell surface HER2 protein.
[0094] See also Figure 7 The experimental results showed that obvious green fluorescence could be observed in the HER2 2+ and HER2 3+ groups of specimens with high HER2 expression, while only weak green fluorescence was observed in the HER2- and HER2 1+ groups of tissue specimens with low HER2 expression. The above results show that the HER2 protein in situ detection strategy of nucleotide-modified covalent G4 DNA enzyme efficient catalysis and PER amplification still has good specificity for clinical samples.
[0095] Figure 6 and Figure 7 The combination can illustrate that the combination of nucleotide-modified covalent G4 DNA enzyme and PER isothermal amplification technology can achieve highly sensitive fluorescence in situ imaging of HER2 protein on the tumor surface of tumor cells and tissue samples.
[0096] Example 2
[0097] As shown in Table 2, this example compares and analyzes the catalytic ability of the nucleotide-modified covalent G4 DNA enzyme of the present invention with that of the DNA enzymes disclosed in the invention patents CN107119031A and CN111705044A.
[0098] Table 2
[0099] source G4 sequence name Sequence (5'-3') CN107119031A A5A AGGGGGA CN111705044A G4TC TTGGGTGGGTGGGTGGGTC The present invention Co-G4TC / H TTGGGTGGGTGGGTGGGTC-Hemin The present invention Co-G4A / H GGGTGGGTGGGTGGGAAA-Hemin
[0100] The specific experimental methods are as follows:
[0101] A5A and G4TC were mixed with the same concentration of Hemin and reacted at 25 degrees for 30 minutes to form nucleotide-modified non-covalent G4 DNA enzymes A5A / H and G4TC / H, and the catalytic performance of the two was compared with the nucleotide-modified covalent G4 DNA enzymes Co-G4TC / H and Co-G4A / H in the present invention. The catalytic system is as follows:
[0102] Buffer: 50 mM Tris-HCl buffer (pH 7, 25 mM KCl); ABTS 2- Reaction concentration: 2mM; H2O2 concentration: 1mM; four DNA enzyme concentrations: 45nM; reaction time: 3min; reaction temperature: 25℃; protected from light. UV-vis absorption spectrum detection: collect UV-vis absorption spectrum of products in the range of 400-500nm and analyze the products. Colorimetric kinetic experiments were performed at 418nm and the reaction time was 120 seconds.
[0103] The results are as follows Figure 8 As shown in A and 8B: The nucleotide-modified covalent G4 DNA enzymes Co-G4TC / H and Co-G4A / H constructed by the present invention have better catalytic ability than the representative DNA enzymes A5A / H and G4TC / H established by invention patents CN107119031A and CN111705044A, wherein the catalytic rate of Co-G4A / H is 885.9nM / S, which is about 16.9 times that of A5A / H (52.3nM / S). At the same time, the catalytic rate of Co-G4TC / H (382.1nM / S) is also greater than that of non-covalent G4TC / H (140.7nM / S). The above results show that the catalytic ability of the nucleotide-modified G4 DNA enzyme constructed by covalent means is significantly higher than that of the non-covalent G4 DNA enzyme.
[0104] The above embodiments are merely illustrative of the principles and effects of the present invention, and are not intended to limit the present invention. Anyone familiar with the art may modify or alter the above embodiments without departing from the spirit and scope of the present invention. Therefore, all equivalent modifications or alterations made by a person of ordinary skill in the art without departing from the spirit and technical concept disclosed by the present invention shall still be covered by the claims of the present invention.
Claims
1. A nucleotide-modified covalent G4 DNA enzyme, characterized in that The invention comprises hemin, a ligand nucleotide and a G-quadruplex structure covalently bound in sequence through an amide reaction, wherein the ligand nucleotide is modified at the 3' end and / or the 5' end of the G-quadruplex structure, and the ligand nucleotide comprises 1 to 3 bases, wherein the base of the ligand nucleotide is selected from at least one of adenine A, thymine T and cytosine C.
2. The nucleotide-modified covalent G4 DNA enzyme according to claim 1, characterized in that: The nucleotide sequence of the G-quadruplex structure is GGGTGGGTGGGTGGG.
3. The nucleotide-modified covalent G4 DNA enzyme according to claim 1, characterized in that: The base of the ligand nucleotide is selected from adenine A and / or thymine T.
4. The nucleotide-modified covalent G4 DNA enzyme according to claim 1, characterized in that: The ligand nucleotide is modified at the 3' end of the G-quadruplex structure.
5. The nucleotide-modified covalent G4 DNA enzyme according to claim 1, characterized in that: The nucleotide sequence of the nucleotide-modified covalent G4 DNA enzyme is selected from at least one of SEQ ID NOs. 1 to 19.
6. The method for preparing the nucleotide-modified covalent G4 DNA enzyme according to any one of claims 1 to 5, characterized in that: include: Hemin, ligand nucleotide and G-quadruplex structure are covalently bound in sequence through amide reaction to prepare the nucleotide-modified covalent G4 DNA enzyme.
7. An in vitro diagnostic composition, characterized in that: The invention relates to a nucleotide-modified covalent G4 DNA enzyme according to any one of claims 1 to 5 and / or a nucleotide-modified covalent G4 DNA enzyme prepared according to the method of claim 6.
8. The in vitro diagnostic composition according to claim 7, wherein: Also included are peroxidase substrates and hydrogen peroxide.
9. The in vitro diagnostic composition according to claim 7, wherein: It also includes a first probe, a second probe and fluorescein tyramide, wherein the first probe is composed of a human epidermal growth factor receptor-2 aptamer and a primer exchange reaction amplification primer sequence, and is used to identify the human epidermal growth factor receptor-2 protein; the second probe is composed of the nucleotide-modified covalent G4DNA enzyme sequence and a primer exchange reaction amplification chain complementary sequence, and the primer exchange reaction amplification chain complementary sequence is a long single-stranded complementary sequence generated by amplifying the primer exchange reaction amplification primer sequence through multi-stage primer exchange reaction.
10. Use of the nucleotide-modified covalent G4 DNA enzyme according to any one of claims 1 to 5 and / or the nucleotide-modified covalent G4 DNA enzyme prepared according to the method of claim 6 and / or the in vitro diagnostic composition according to any one of claims 7 to 9 in the preparation of in vitro diagnostic reagents and / or the development of in vitro diagnostic systems.
Citation Information
Patent Citations
Probe based on G-quadruplex-chlorine heme DNA enzyme and application of probe
CN105018474A
Novel thermophilic quaternary G quadruplex DNAase
CN107119031A
Construction of novel controllable high-activity G quadruplex DNA enzyme
CN111705044A
Comprehensive chemical modification method of G-four-chain aptamer, product and application thereof in anti-multidrug resistant tumour cells
CN113373155A
Method for detecting biomolecules based on G4 nucleic acid aptamer
CN114199859A
Cited By
Covalently modified DX-G4-H DNA enzyme based on double-cross structure constraint, construction method thereof and high-sensitivity detection platform
CN122214336A
